Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Biweekly fotemustine schedule for recurrent glioblastoma in the elderly: activity and toxicity assessment of a multicenter study.

Addeo R, Lamberti G, Simonetti G, Iodice P, Marinelli A, Montella L, Cappabianca S, Gaviani P, Caraglia M, Prete SD, Silvani A.

CNS Oncol. 2019 Jun 1;8(2):CNS32. doi: 10.2217/cns-2019-0004. Epub 2019 Jul 10.

2.

Clinical outcome of an alternative fotemustine schedule in elderly patients with recurrent glioblastoma: a mono-institutional retrospective study.

Lombardi G, Bellu L, Pambuku A, Della Puppa A, Fiduccia P, Farina M, D'Avella D, Zagonel V.

J Neurooncol. 2016 Jul;128(3):481-6. doi: 10.1007/s11060-016-2136-7. Epub 2016 May 11.

PMID:
27165580
3.

High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients: A phase I/II trial.

Marinelli A, Lamberti G, Cerbone L, Cordua N, Buonerba C, Peluso G, Di Lorenzo G, De Placido S.

Medicine (Baltimore). 2018 Jul;97(27):e11254. doi: 10.1097/MD.0000000000011254.

4.

GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status.

Pérez-Segura P, Manneh R, Ceballos I, García A, Benavides M, Fuster J, Vaz MA, Cano JM, Berros JP, Covela M, Moreno V, Quintanar T, García Bueno JM, Fernández I, Sepúlveda J.

Clin Transl Oncol. 2016 Aug;18(8):805-12. doi: 10.1007/s12094-015-1444-2. Epub 2015 Nov 5.

PMID:
26542177
5.

A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma.

Addeo R, Caraglia M, De Santi MS, Montella L, Abbruzzese A, Parlato C, Vincenzi B, Carraturo M, Faiola V, Genovese M, Cennamo G, Del Prete S.

J Neurooncol. 2011 May;102(3):417-24. doi: 10.1007/s11060-010-0329-z. Epub 2010 Aug 10. Erratum in: J Neurooncol. 2011 May;102(3):425. Dosage error in published abstract; MEDLINE/PubMed abstract corrected.

6.

Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience.

Scoccianti S, Detti B, Sardaro A, Iannalfi A, Meattini I, Leonulli BG, Borghesi S, Martinelli F, Bordi L, Ammannati F, Biti G.

Anticancer Drugs. 2008 Jul;19(6):613-20. doi: 10.1097/CAD.0b013e3283005075.

PMID:
18525321
7.

A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma.

Fabrini MG, Silvano G, Lolli I, Perrone F, Marsella A, Scotti V, Cionini L.

J Neurooncol. 2009 Mar;92(1):79-86. doi: 10.1007/s11060-008-9739-6. Epub 2008 Nov 19.

PMID:
19018476
8.

AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma.

Brandes AA, Finocchiaro G, Zagonel V, Reni M, Caserta C, Fabi A, Clavarezza M, Maiello E, Eoli M, Lombardi G, Monteforte M, Proietti E, Agati R, Eusebi V, Franceschi E.

Neuro Oncol. 2016 Sep;18(9):1304-12. doi: 10.1093/neuonc/now035. Epub 2016 Mar 6.

9.

Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology).

Soffietti R, Trevisan E, Bertero L, Cassoni P, Morra I, Fabrini MG, Pasqualetti F, Lolli I, Castiglione A, Ciccone G, Rudà R.

J Neurooncol. 2014 Feb;116(3):533-41. doi: 10.1007/s11060-013-1317-x. Epub 2013 Dec 1.

10.

Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

Brandes AA, Tosoni A, Franceschi E, Blatt V, Santoro A, Faedi M, Amistà P, Gardiman M, Labianca R, Bianchini C, Ermani M, Reni M.

Cancer Chemother Pharmacol. 2009 Sep;64(4):769-75. doi: 10.1007/s00280-009-0926-8. Epub 2009 Jan 24.

11.

Low-dose fotemustine as second-line chemotherapy for recurrent glioblastoma multiforme.

De Felice F, Bulzonetti N, Musio D, D'Elia A, Salvati M, Tombolini V.

Anticancer Res. 2013 Sep;33(9):4013-6.

PMID:
24023343
12.

Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma.

Santoni M, Scoccianti S, Lolli I, Fabrini MG, Silvano G, Detti B, Perrone F, Savio G, Iacovelli R, Burattini L, Berardi R, Cascinu S.

J Neurooncol. 2013 Jul;113(3):397-401. doi: 10.1007/s11060-013-1125-3. Epub 2013 Apr 6.

13.

Concurrent radiotherapy: fotemustine combination for newly diagnosed malignant glioma patients, a phase II study.

Beauchesne PD, Taillandier L, Bernier V, Carnin C.

Cancer Chemother Pharmacol. 2009 Jun;64(1):171-5. doi: 10.1007/s00280-009-0993-x. Epub 2009 Apr 8.

PMID:
19352662
14.

Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients.

Silvani A, Lamperti E, Gaviani P, Eoli M, Fiumani A, Salmaggi A, Falcone C, Filippini G, Botturi A, Boiardi A.

J Neurooncol. 2008 Apr;87(2):143-51. Epub 2007 Jun 19. Erratum in: J Neurooncol. 2008 Apr;87(2):153. J Neurooncol. 2008 Aug;89(1):119.

PMID:
17576523
15.

Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial.

Leyvraz S, Piperno-Neumann S, Suciu S, Baurain JF, Zdzienicki M, Testori A, Marshall E, Scheulen M, Jouary T, Negrier S, Vermorken JB, Kaempgen E, Durando X, Schadendorf D, Gurunath RK, Keilholz U.

Ann Oncol. 2014 Mar;25(3):742-6. doi: 10.1093/annonc/mdt585. Epub 2014 Feb 7.

16.

Lecture: fotemustine in brain tumors.

Silvani A, Gaviani P, Lamperti E, Botturi A, Ferrari D, Simonetti G, Salmaggi A.

Neurol Sci. 2011 Nov;32 Suppl 2:S255-7. doi: 10.1007/s10072-011-0800-4.

PMID:
21987288
17.

Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.

Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M, Neuber K, Bieber T, Gilde K, Guillem Porta V, Fra J, Bonneterre J, Saïag P, Kamanabrou D, Pehamberger H, Sufliarsky J, Gonzalez Larriba JL, Scherrer A, Menu Y.

J Clin Oncol. 2004 Mar 15;22(6):1118-25.

PMID:
15020614
18.

Second-line chemotherapy with dacarbazine and fotemustine in nitrosourea-pretreated patients with recurrent glioblastoma multiforme.

Fazeny-Dörner B, Veitl M, Wenzel C, Piribauer M, Rössler K, Dieckmann K, Ungersböck K, Marosi C.

Anticancer Drugs. 2003 Jul;14(6):437-42.

PMID:
12853885
19.

Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas.

Vaccaro V, Fabi A, Vidiri A, Giannarelli D, Metro G, Telera S, Vari S, Piludu F, Carosi MA, Villani V, Cognetti F, Pompili A, Marucci L, Carapella CM, Pace A.

Biomed Res Int. 2014;2014:351252. doi: 10.1155/2014/351252. Epub 2014 May 4.

20.

Adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of recurrent high-grade glioma.

Ji N, Weng D, Liu C, Gu Z, Chen S, Guo Y, Fan Z, Wang X, Chen J, Zhao Y, Zhou J, Wang J, Ma D, Li N.

Oncotarget. 2016 Jan 26;7(4):4369-78. doi: 10.18632/oncotarget.6737.

Supplemental Content

Support Center